GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
35.27
-0.09 (-0.25%)
Jan 31, 2025, 4:00 PM EST - Market closed
GSK Revenue
GSK had revenue of 8.01B GBP in the quarter ending September 30, 2024, a decrease of -1.66%. This brings the company's revenue in the last twelve months to 31.31B, up 5.59% year-over-year. In the year 2023, GSK had annual revenue of 30.33B with 3.42% growth.
Revenue (ttm)
31.31B GBP
Revenue Growth
+5.59%
P/S Ratio
n/a
Revenue / Employee
445,949 GBP
Employees
70,212
Market Cap
71.26B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
GSK News
- 5 days ago - Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand - GlobeNewsWire
- 11 days ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 18 days ago - Hallucinations in AI: How GSK is addressing a critical problem in drug development - VentureBeat
- 18 days ago - Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals - CNBC
- 18 days ago - GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 19 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 19 days ago - Drugmakers rush to sign deals on first day of industry conference - Reuters
- 19 days ago - GSK to buy US biotech firm IDRx for up to $1.15 billion - Reuters